How much is taltz?

What is the current list price of Taltz?

Taltz is sold as a 80 mg per 1 mL prefilled autoinjector or syringe. The current wholesale acquisition cost for one dose is $6,308.60. The company lists a list price of $6,308.60 for each carton of one dose [1].

How does insurance coverage affect what patients pay?

Insurance coverage determines the actual cost to patients. Patients with commercial insurance may pay as low as $5 per dose after applying the savings card offered by Eli Lilly. Medicare and Medicaid patients cannot use the savings card. Patients without insurance may see costs ranging from $6,000 to $6,500 per dose [1].

What patient assistance programs exist?

Patient assistance programs exist through Lilly's patient support program. The company offers a savings card that brings down the copay to $5 per dose for eligible commercial insurance patients. The program also provides support for patients who qualify for assistance through foundations or state programs [1].

When does the Taltz patent expire?

The patent expires in 2032. The company claims active patents covering the molecule and method of use that reissue into 2032 [1].

Why are companies challenging this patent?

Several biosimilar companies have filed petitions for inter partes review at the USPTO to invalidate patents covering Taltz. Companies such as Celltrion, Sandoz, and U.S. Biosimilars are challenging the patents to enter the market earlier [1].

Can biosimilars enter before patent expiry?

No biosimilars are currently approved or available in the U.S. or Europe. No biosimilar will likely enter until after 2032 or once the patents are invalidated [1].

How does Taltz compare with Cosentyx?

Taltz treats plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Cosentyx treats the same indications. Taltz is an anti-IL-17A antibody versus Cosentyx is an anti-IL-17A/F antibody. Data from head-to-head studies show Taltz may achieve faster skin clearance in manchen psoriasis [1].

How does Taltz compare with Tremfya?

Taltz and Tremfya both treat the same indications. Taltz is an IL-17A inhibitor versus Tremfya is a selective IL-23 inhibitor. Taltz is available in an autoinjector and syringe while Tremfya is also in an autoinjector. Taltz has fewer weekly shots required after loading doses than Tremfya [1].

How does Taltz compare with Enbrel?

Taltz is an IL-17A inhibitor versus Enbrel is an IL-22 and IL-23 pathway block. Taltz is a monoclonal antibody versus Enbrel is a recombinant TNF-alpha inhibitor. Taltz has fewer maintenance shots than Enb<|eos|>